Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: olumacostat glasaretil, pf-05175157, clesacostat +1 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 4 pathways; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 11677
Sealed predictions
- ACACB in dopamine neurons, braak-0.72 (p 0.029) → -0.20 (p 0.601)receipt 11684
Swarm cases
receipt 11684: ACACB in dopamine neurons, braak
- power
- full sample -0.40 (p 0.097, n 18), 95% CI -0.73 to +0.08. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.38 (p 0.116, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.44 (p 0.064, n 18). could be the mix.
- skeptic
- leave-one-out range -0.49 to -0.32, sign flips 0; without severely affected donors -0.40 (p 0.097, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ACACB in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts